The new analyzes of NADIM II presented by the president of the Spanish Lung Cancer Group (GECP), Mariano Provencio, show that this new treatment will allow a greater number of patients to be operated on and raise cure rates for intermediate tumors, without metastases.
The study, in which 86 patients from twenty Spanish hospitals participated, shows an overall survival of 84.7% in cases treated with chemotherapy and the immunotherapy drug nivolmab, compared to 63.4% treated with the conventional method, with chemotherapy alone.
In addition, research presented at the presidential session of the IASLC World Lung Congress 2022 concludes that progression-free survivalthat is, without the tumor expanding, was 66% in 24 monthscompared to 44% of the group that received conventional treatment.
With this combination of drugs, both overall and progression-free survival increases above 20% before surgery, which is a paradigm shift by opening up this new treatment possibility for patients with intermediate-stage lung cancer.
As Mariano Provencio declared to EFE, “NADIM II confirms the superiority of this combination in cases with potentially operable tumors.” In addition, the president of the GECP highlighted that in many cases with large tumors “the most immulab combination of chemotherapy they achieve not only that it is reduced, but in many cases the disease disappears”.
Long-term tumor shrinkage
The study also proves its long-term validity., since after two years, 36.8% of patients achieve a complete reduction of the tumor, compared to 6% who do it with the traditional approach. In addition, 69% of the cases that were only treated with chemotherapy opted for surgery, while 93% of those assisted with the new technique were able to undergo it.
The treatment has already been approved by a special procedure by the US drug regulatory agency (FDA) and It is available in North American hospital centers. Oncologist Mariano Provencio concluded in his statements to EFE that he hopes “Europe, and therefore Spain, will follow this path because, without a doubt, is a clear benefit for patients with a high-impact tumor”.
–
